MAM
Great Learning becomes overseas team sponsor of Sri Lanka Cricket
Mumbai: Great Learning, a global ed-tech company for higher and professional education and a part of the BYJU’S group has partnered with Sri Lanka Cricket as the official overseas team sponsor. The company’s branding can be spotted for the first time on the Sri Lankan Cricket team’s jersey during the upcoming India vs Sri Lanka T20 series, which starts on 24 February in Lucknow.
This partnership comes at a time when Great Learning is expanding its global footprint and seeing tremendous growth from key international markets, according to the company. “Great Learning has reported increasing demand for its upskilling programs from working professionals as well as enterprises in South Asia including Sri Lanka. The company is looking to enhance its brand awareness in the region through an association with cricket, which is a widely followed sport in Sri Lanka,” it further said.
Sharing his thoughts on the partnership, Great Learning co-founder Arjun Nair said, “Great Learning has created multiple brand associations with cricket given how well it resonates with our target audience. We are excited to come on board as the Official Overseas Team Sponsor of Sri Lanka Cricket. The sport is widely followed by the youth in this region and we are confident that this association will create a lot of awareness for Great Learning and demand for upskilling in general.”
‘’Sports and Education goes hand in hand, and I believe the latest partnership will augur well for Great Learning, as the collaboration will help our partner to drive its intended message to the desired audience, as Sri Lanka Cricket is keenly followed by people from all walks of life, especially the younger generation,’’ said Sri Lanka Cricket CEO Ashley De Silva.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
